Literature DB >> 10664160

Fabry disease: ultrastructural lectin histochemical analyses of lysosomal deposits.

A Kanda1, S Nakao, S Tsuyama, F Murata, T Kanzaki.   

Abstract

Fabry disease is an X-linked inborn error of glycosphingolipid catabolism resulting from a deficiency of lysosomal alpha-galactosidase activity. Globotriaosylceramide accumulates predominantly in lysosomes of various tissues. Former studies have clarified the nature of this disease, and the accumulated materials in the lysosomes have been analyzed using biochemical techniques. In the present study, transmission electron microscopy was used to reveal the fine structure of these lysosomal deposits, and sugar residues in the lysosomal deposits in Fabry disease were examined by lectin histochemistry combined with enzyme digestion. This is the first report to describe the lysosomal sugar residues in Fabry disease analyzed using lectin histochemistry at the ultrastructural level. With these techniques, we were able to detect alpha-galactosyl, beta-galactosyl and glucosyl sugar residues in the lysosomal deposits. The experimental procedures used in this study have considerable potential for use in investigations of glycolipid and glycoprotein storage diseases without the need for complex methodology and expensive materials.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10664160     DOI: 10.1007/pl00008196

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  7 in total

1.  Cellular and tissue localization of globotriaosylceramide in Fabry disease.

Authors:  Hasan Askari; Christine R Kaneski; Cristina Semino-Mora; Priya Desai; Agnes Ang; David E Kleiner; Lorah T Perlee; Martha Quezado; Linda E Spollen; Brandon A Wustman; Raphael Schiffmann
Journal:  Virchows Arch       Date:  2007-08-03       Impact factor: 4.064

2.  Intravascular ultrasound assessment of coronary artery involvement in Fabry disease.

Authors:  T Kovarnik; G S Mintz; D Karetova; J Horak; J Bultas; R Skulec; H Skalicka; M Aschermann; M Elleder; A Linhart
Journal:  J Inherit Metab Dis       Date:  2008-11-08       Impact factor: 4.982

3.  Globotriaosylsphingosine accumulation and not alpha-galactosidase-A deficiency causes endothelial dysfunction in Fabry disease.

Authors:  Mehdi Namdar; Catherine Gebhard; Rafael Studiger; Yi Shi; Pavani Mocharla; Christian Schmied; Pedro Brugada; Thomas F Lüscher; Giovanni G Camici
Journal:  PLoS One       Date:  2012-04-30       Impact factor: 3.240

4.  Expression of uPAR in Urinary Podocytes of Patients with Fabry Disease.

Authors:  Hernán Trimarchi; Romina Canzonieri; Amalia Schiel; Juan Politei; Cristian Costales-Collaguazo; Aníbal Stern; Matías Paulero; Tatiana Rengel; Lara Valiño-Rivas; Mariano Forrester; Fernando Lombi; Vanesa Pomeranz; Romina Iriarte; Alexis Muryan; Alberto Ortiz; María Dolores Sanchez-Niño; Elsa Zotta
Journal:  Int J Nephrol       Date:  2017-04-24

5.  Low bone mineral density due to secondary hyperparathyroidism in the GlatmTg(CAG-A4GALT) mouse model of Fabry disease.

Authors:  Hiroki Maruyama; Atsumi Taguchi; Mariko Mikame; Hongmei Lu; Norihiro Tada; Muneaki Ishijima; Haruka Kaneko; Mariko Kawai; Sawako Goto; Akihiko Saito; Riuko Ohashi; Yuji Nishikawa; Satoshi Ishii
Journal:  FASEB Bioadv       Date:  2020-06-10

6.  Enzyme replacement reverses abnormal cerebrovascular responses in Fabry disease.

Authors:  David F Moore; Gheona Altarescu; Peter Herscovitch; Raphael Schiffmann
Journal:  BMC Neurol       Date:  2002-06-18       Impact factor: 2.474

7.  Medullary thick ascending limb impairment in the GlatmTg(CAG-A4GALT) Fabry model mice.

Authors:  Hiroki Maruyama; Atsumi Taguchi; Yuji Nishikawa; Chu Guili; Mariko Mikame; Masaaki Nameta; Yutaka Yamaguchi; Mitsuhiro Ueno; Naofumi Imai; Yumi Ito; Takahiko Nakagawa; Ichiei Narita; Satoshi Ishii
Journal:  FASEB J       Date:  2018-03-19       Impact factor: 5.191

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.